Patent ID: 8858943

Claim:
A method of treating a human patient afflicted with age-related macular degeneration (AMD), glaucoma or β-amyloid dependent cataract formation, which method comprises the step of administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment and/or derivative thereof which binds β-antyloid peptide and which comprises the following CDRs: CDRH1: DNGMA (SEQ ID No: 1) CDRH2: FISNLAYSIDYADTVTG (SEQ ID No: 2) CDRH3: GTWFAY (SEQ ID No: 3) within a human heavy chain variable region originating from the VH 3 gene family and: CDRL1: RVSQSLLHSNGYTYLH (SEQ ID No: 4) CDRL2: KVSNRFS (SEQ ID No: 5) CDRL3: SQTRHVPYT (SEQ ID No: 6) within a human light chain variable region originating from the amino acid sequence disclosed in GenPept entry GAAS1135 (SEQ ID No:241).